Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
As-needed budesonide + formoterol versus terbutaline or regular budesonide in mild intermittent asthma
2009-012805-20Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma and exercise-induced bronchospasm (EIB) comparing As-needed budesonide + formoterol, As-needed terbutaline and Regular once-daily budesonide plus as-needed terbutaline (3 arms). Primary endpoints: Primary efficacy endpoint 1 and Primary efficacy endpoint 2. Started May 2009; status: completed.
02
Drugs
budesonideformoterolterbutaline
03
Conditions
asthmaexercise-induced bronchospasm (EIB)
Beyond the preview
Go deeper on 2009-012805-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012805-20.